MacuLogix closes $38.7M financing round — 4 insights

Macular degeneration solutions company MacuLogix closed a $38.7 million financing round, Invision reports.

What you should know:

1. MacuLogix provides instruments, tools and education to treat age-related macular degeneration patients.

2. Vivo Capital led the series D round, with contributions from four other firms.

3. MacuLogix raised a $51 million in venture funding and $10 million in venture debt.

4. "With this funding and the addition of Vivo Capital, we are fully backed by a strategic group of investors who support our company's vision to eliminate blindness caused by AMD," said MacuLogix CEO and President William D. McPhee.

More articles on leadership:
How total joints propelled an Ohio-based ASC's strategy for growth and a bigger location
Fox Valley Orthopedics' Dr. Vishal Mehta on total joint replacement
Orthopedic trauma, spine & more: 3 trends, growth areas for ASCs

© Copyright ASC COMMUNICATIONS 2020. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.


Featured Webinars

Featured Whitepapers